^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Rintega (rindopepimut)

i
Other names: CDX- 110, PF-04948568
Associations
Company:
Celldex
Drug class:
EGFR inhibitor
Related drugs:
Associations
1year
Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma. (PubMed, Vaccines (Basel))
For example, the CDX-110 (rindopepimut) NeoAg peptide vaccine derived from the EGFRvIII deletion mutant in combination with temozolomide and radiotherapy has shown efficacy in treating EGFRvIII-harboring glioblastoma multiforme (GBM) patients undergone surgery in multiple Phase I and II clinical trials. The efficacy of NeoAg-targeting peptide vaccines may be further improved by combining with other modalities such as tyrosine kinase or immune checkpoint inhibitor (ICI) therapy, which are currently being tested in animal models and clinical trials. Herein, we review the most current basic and clinical research progress on EGFR-targeted peptide vaccination for the treatment of NSCLC and other solid tumor types.
Review • Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
temozolomide • Rintega (rindopepimut)
almost2years
Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors. (PubMed, Adv Exp Med Biol)
With respect to cancer vaccines, rindopepimut has been well-studied in glioblastoma (GBM) patients with the EGFRvIII mutation, with early results from phase II trials showing possible efficacy in carefully selected GBM patients...However, it is important to keep in mind that the field is still in its infancy and many clinical trials are still early-phase. Several, clinical trials are currently underway to further explore the role of immunotherapy for CNS malignancies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • IL2 (Interleukin 2)
|
EGFR mutation • HER-2 mutation • EGFRvIII mutation
|
Rintega (rindopepimut)
over3years
Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials. (PubMed, Chin J Cancer Res)
Regorafenib, rindopepimut and neoadjuvant programmed death 1 (PD-1) inhibitors are promising agents for rGBM, while regorafenib is effective in both O-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated patients. Temozolomide rechallenge and alkylating agents combined with bevacizumab can be useful for patients with MGMT methylation, and patients with isocitrate dehydrogenase (IDH) mutations or second recurrence can benefit from vocimagene amiretrorepvec (Toca 511). Some phase I trials on targeted therapy and immunotherapy have shown positive results, and results from further studies are expected. In addition to the analysis of existing clinical trial results, forthcoming trials should be well designed, and patients are encouraged to participate in appropriate clinical trials.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
Avastin (bevacizumab) • temozolomide • Stivarga (regorafenib) • Rintega (rindopepimut) • vocimagene amiretrorepvec/extended release flucytosine (DB107)